-
August 9, 2021 Surveys Show: America’s Public Approval of Psychedelic Therapy Lags Behind CanadaWe compare two polls of roughly the same sample size in two neighboring countries, and...
-
August 3, 2021 Australia’s First Psychedelic Research Institute Opens with $40 Million InvestmentPsychae Institute will collaborate with other clinical research organizations to develop novel psychedelic medicines and...
-
August 2, 2021 How the Heroic Hearts Project Is Spearheading Psilocybin Research to Treat Veterans for TBIDr. Grace Blest-Hopley tells Psychedelic Spotlight that the compound has anti-inflammatory effects on the brain,...
-
July 29, 2021 Oregon Psilocybin Advisory Board Finds the Psychedelic Reduces Depression and AnxietyThe subcommittee’s review is the largest of its kind to be conducted in the state,...
-
July 27, 2021 Ayahuasca May Help Curb Drug and Alcohol AddictionNew study compiles the experiences of 8,629 ayahuasca users from 40 different countries, and results...
-
July 23, 2021 How a Psilocybin Study on AIDS Survivors Could Solve a Big Problem with Psychedelic TherapyA group psilocybin study paves the way for increased scalability of novel treatments that typically...
-
July 21, 2021 Wake Network Partners with Lieber Institute to Develop Genetics-Based Screening System for Psychedelic TherapiesFungi bioscience company describes the project as “one of the most robust genetics research initiatives...
-
July 16, 2021 How Wesana Health CEO Daniel Carcillo Plans to Protect Athletes From Traumatic Brain InjuryAnd why the two-time Stanley Cup champion does not imagine working with the NHL in...
-
July 15, 2021 COVID-19 Pandemic Study of Ketamine Therapy Amplifies Antidepressant PotentialStudy authors even believe "treating serious mental illness may reduce adverse outcomes related to COVID-19."
-
July 13, 2021 Awakn Life Sciences CEO Details ‘Groundbreaking’ MDMA Discovery in Quest to Treat AddictionAnthony Tennyson tells the Psychedelic Spotlight Podcast that his company has "discovered receptor sites that...
